Remondel, Noyal-Chatillon-sur-Seiche, France

Regis Dolaine


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Regis Dolaine

Introduction: Regis Dolaine hails from Remondel, Noyal-Chatillon-sur-Seiche, France, and is recognized for his inventive work in pharmaceutical chemistry. With a focus on Azaindole derivatives, he has made significant contributions to the field of pain management through his innovative spirit.

Latest Patents: Dolaine is the inventor of a patent titled "Azaindole derivatives, preparations thereof, uses thereof and compositions containing them." This patent describes compounds of formula I, including various pharmaceutically acceptable salts. The compounds are valuable in therapeutic applications, particularly in the management of pain, showcasing Dolaine's commitment to improving healthcare outcomes.

Career Highlights: Regis Dolaine currently works at AstraZeneca AB, a leading global biopharmaceutical company. His role within the company emphasizes his expertise in pharmaceutical research, particularly in developing compounds that address unmet medical needs.

Collaborations: Throughout his career, Dolaine has collaborated with notable colleagues, including Zhongyong Wei and Christopher Walpole. These partnerships reflect the collaborative nature of scientific innovation, allowing for the sharing of ideas and expertise to further advance their research initiatives.

Conclusion: Regis Dolaine's contributions to the field of pharmaceuticals, especially through his patent on Azaindole derivatives, underline the importance of innovation in developing effective therapies. His work not only enhances our understanding of pain management but also exemplifies the collaborative efforts within the scientific community aimed at advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…